Gastrointestinal

The Pharmacy Times® Gastrointestinal resource center provides news and articles centered around the FDA approved drugs in gastroenterology, as well as links to condition-specific resources, and videos and other content.

What can we help you find?

Monday Pharmaceutical Mystery: April 6

What are you going to recommend for a customer who was unable to complete a previously recommended regimen?

Series of Studies Identifies Predictive Tools for Crohn Disease

In a series of studies, researchers described the identification of predictive tools and a new understanding of environmental factors that trigger inflammatory bowel disease.

Crohn Disease Management Presents Challenges

The goal of therapy centers on improving quality of life, maintaining remission, and preventing hospitalization and surgery.

Monday Pharmaceutical Mystery: March 16

How can this patient better tolerate polyethylene glycol (PEG)-electrolyte lavage solution?

Pre-Measured Omeprazole Suspension Kit Offers More Stability, Longer Duration Than Traditional Suspension

FIRST Omeprazole Kits offer a pre-measured option for pharmacists dispensing suspended Omeprazole.

Tofacitinib Found to Repair Permeability Defects in the Gut for Patients with Ulcerative Colitis

Tofacitinib, currently used to treat rheumatoid arthritis and ulcerative colitis, has a correcting effect on defects that occur in inflammation.

Opioid-Induced Constipation: Conversations With HCPs

Shared insight on the open dialogues that should take place between patients with opioid-induced constipation and care providers.

Goals of Managing OIC & Prophylactic Strategies

Key opinion leaders provide their perspectives on the goals of therapy and prophylactic management of opioid-induced constipation.

Opioid-Induced Constipation: Diagnosis & Treatment Guidelines

A comprehensive review of opioid-induced constipation diagnosis strategies and foundational treatment guidelines.

Opioid-Induced Constipation: Pathophysiology & Disease Burden

A panel of experts considers the disease pathology of opioid-induced constipation and the burden it has on patients.

Company Halts Ranitidine Production Over NDMA Contamination Concerns

After some lots of ranitidine were found to contain small amounts of N-nitrosodimethylamine (NDMA), Novartis's Sandoz unit has announced that they are halting distribution of ranitidine (Zantac) products until the contamination concerns are resolved.

FDA Approves New Packaging for OTC Loperamide Products

Officials from the FDA have announced an approved package size and package type limit for over-the-counter (OTC) brand-name tablet and capsule forms of loperamide.

The Pharmacy Times® Gastrointestinal resource center provides a source of all the latest clinical information, with articles covering updates from the robust pipeline of novel GI therapies, and the newest data from all phases of clinical trials and studies in the space. It also serves as a hub of information and news from the upcoming and ongoing conferences and annual meetings of gastrointestinal associations and societies, including pivotal coverage right from the floor.

Among its other resources are a wealth of videos including interviews with thought leaders and experts in GI, and moderated Peer Exchange panel discussions about the best practices and key methods for treating complex cases of conditions such as: constipation, irritable bowel syndrome, hemorrhoids, anal fissures, perianal abscesses, anal fistulas, perianal infections, diverticular diseases, colitis, colon polyps and cancer.